Lung AI (LAI001)

K243239

Exo Inc · cleared 2025-04-24 · product code MYN · Radiology

Premarket evidence — what FDA accepted

Device typesamd
source quote (p.4)
Lung AI software device is a Computer-Aided Detection (CADe) tool designed to assist in the detection of consolidation/atelectasis and pleural effusion during the review of lung ultrasound scans.
AlgorithmSupervised Deep Learning including Deep Convolutional Neural Networks for Segmentation, Landmark Detection and Classification
source quote (p.8)
Supervised Deep Learning including Deep Convolutional Neural Networks for Segmentation, Landmark Detection and Classification
Adaptive (vs locked)No
source quote (p.7)
Artificial intelligence, including non-adaptive machine learning algorithms trained with clinical data
PCCPFDA source did not state this
Cybersecurity addressedYes
source quote (p.8)
Cybersecurity testing was performed in accordance with Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions.

Validation studies (2)

Retrospective clinical

n=359 patients · 6 site(s)

standards: IEC 62304:2006/AC:2015 - Medical device software – Software life cycle processes, Content of Premarket Submissions for Device Software Functions, Guidance for Industry and Food and Drug Administration Staff, Computer-Assisted Detection Devices Applied to Radiology Images and Radiology Device Data Premarket Notification [510(k)] Submissions, Clinical Performance Assessment: Considerations for Computer-Assisted Detection Devices Applied to Radiology Images and Radiology Device Data in Premarket Notification (510(k)) Submissions

Reader study (MRMC)

n=322 patients

endpoints: improvement of at least 2% in overall reader performance, as measured by AUC-ROC, when aided by the device

Reported performance (20 observations)

sensitivityas written: “Sensitivity (Pleural Effusion Detection)0.97CI 95% CI 0.94 – 0.99
source quote (p.9)
Se = 0.97 (95% CI 0.94 – 0.99)
specificityas written: “Specificity (Pleural Effusion Detection)0.91CI 95% CI 0.87 – 0.96
source quote (p.9)
Sp = 0.91 (95% CI 0.87 – 0.96)
sensitivityas written: “Sensitivity (Consolidation / Atelectasis Detection)0.97CI 95% CI 0.94 – 0.99
source quote (p.9)
Se = 0.97 (95% CI 0.94 – 0.99)
specificityas written: “Specificity (Consolidation / Atelectasis Detection)0.94CI 95% CI 0.90 – 0.98
source quote (p.9)
Sp = 0.94 (95% CI 0.90 – 0.98)
sensitivityas written: “Sensitivity (Pleural Effusion Localization)0.85CI 95% CI 0.80 – 0.89
source quote (p.9)
Se = 0.85 (95% CI 0.80 – 0.89)
specificityas written: “Specificity (Pleural Effusion Localization)0.91CI 95% CI 0.87 – 0.96
source quote (p.9)
Sp = 0.91 (95% CI 0.87 – 0.96)
sensitivityas written: “Sensitivity (Consolidation / Atelectasis Localization)0.86CI 95% CI 0.81 – 0.90
source quote (p.9)
Se = 0.86 (95% CI 0.81 – 0.90)
specificityas written: “Specificity (Consolidation / Atelectasis Localization)0.94CI 95% CI 0.90 – 0.98
source quote (p.9)
Sp = 0.94 (95% CI 0.90 – 0.98)
aurocas written: “AUC-ROC (Pleural Effusion, unaided)0.93CI 95% CI .92 - .94
source quote (p.10)
AUC_unaided = 0.93 (95% CI .92 - .94)
aurocas written: “AUC-ROC (Pleural Effusion, aided)0.96CI 95% CI .95 - .98
source quote (p.10)
AUC_aided = 0.96 (95% CI .95 - .98)
sensitivityas written: “Sensitivity (Pleural Effusion, unaided)0.71CI 95% CI .68 - .75
source quote (p.10)
Se_unaided = 0.71 (95% CI .68 - .75)
sensitivityas written: “Sensitivity (Pleural Effusion, aided)0.88CI 95% CI .86 – .92
source quote (p.10)
Se_aided = 0.88 (95% CI .86 – .92)
specificityas written: “Specificity (Pleural Effusion, unaided)0.96CI 95% CI .95 – .97
source quote (p.10)
Sp_unaided = 0.96 (95% CI .95 – .97)
specificityas written: “Specificity (Pleural Effusion, aided)0.93CI 95% CI .88 – .95
source quote (p.10)
Sp_aided = 0.93 (95% CI .88 – .95)
aurocas written: “AUC-ROC (Consolidation/Atelectasis, unaided)0.92CI 95% CI .91 - .96
source quote (p.10)
AUC_unaided = 0.92 (95% CI .91 - .96)
aurocas written: “AUC-ROC (Consolidation/Atelectasis, aided)0.95CI 95% CI .94 - .98
source quote (p.10)
AUC_aided = 0.95 (95% CI .94 - .98)
sensitivityas written: “Sensitivity (Consolidation/Atelectasis, unaided)0.73CI 95% CI .72 - .80
source quote (p.10)
Se_unaided = 0.73 (95% CI .72 - .80)
sensitivityas written: “Sensitivity (Consolidation/Atelectasis, aided)0.89CI 95% CI .88 – .93
source quote (p.10)
Se_aided = 0.89 (95% CI .88 – .93)
specificityas written: “Specificity (Consolidation/Atelectasis, unaided)0.92CI 95% CI .88 – .93
source quote (p.11)
Sp_unaided = 0.92 (95% CI .88 – .93)
specificityas written: “Specificity (Consolidation/Atelectasis, aided)0.91CI 95% CI .87 – .93
source quote (p.11)
Sp_aided = 0.91 (95% CI .87 – .93)

Each value carries its own analysis unit and task — never compare or pool across devices. Source: 510(k) summary PDF.

Predicate network

Postmarket — what happened after clearance

0
recalls in product code, 24mo
0
MAUDE reports in code, 12mo
-100%
vs code's own 3-yr baseline
0
drift signals on this device

Recall and MAUDE counts are product-code-level (reports aren't reliably attributable to one device). Signals are descriptive observables with sources — never a judgment that the device is unsafe or drifting. Snapshot 2026-07-08.

Reimbursement — how devices like this got paid

Not yet tracked — no payment pathway indexed for this clearance (the reimbursement corpus is a growing seed set).

RIGOR™ Precedent · public FDA/CMS data · descriptive decision-support, not regulatory or reimbursement advice. Share this page: radar.healthai.com/precedent/device/K243239